Tevogen Bio projects $1 billion in revenue from its oncology pipeline in its launch year, with a 5-year estimate of $10-14 billion. The company aims to develop faster and cost-efficient drug models for sustainable medical innovation. Tevogen prioritizes cancer patients’ well-being by focusing on treating SARS-CoV-2 infection in vulnerable patients, such as those undergoing immunosuppressive treatments and chemotherapy. TVGN 489 is being designed to combat the infection in patients with B cell hematologic cancer, along with other cancer types, rheumatoid arthritis, and psoriatic arthritis. Tevogen’s pipeline also includes treatments for Long COVID, cervical cancer, EBV-associated lymphomas, mouth and throat cancer, and multiple sclerosis.

Read more at Total eligible patients in the US exceed 2 million. – Globenewswire.

Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment. – Globenewswire.

Reflects business philosophy of commercial success through patient accessibility. – Globenewswire.: Tevogen Bio Oncology Reports Top-Line Revenue Forecast